Bupropion (Wellbutrin) and Tardive Dyskinesia
Bupropion can be used safely in patients with a history of tardive dyskinesia (TD), as it does not cause or worsen TD and may actually be a preferred antidepressant option in this population.
Key Clinical Points
Bupropion is fundamentally different from the medications that cause TD. TD is caused by dopamine receptor blocking agents (DRBAs), particularly antipsychotics 1, 2, 3. Bupropion is a dopamine/norepinephrine reuptake inhibitor that increases dopaminergic activity rather than blocking it 4. This mechanistic difference makes bupropion an appropriate choice for patients with existing TD.
Safety Profile
The FDA-approved prescribing information for Wellbutrin does not list TD as a contraindication, warning, or adverse effect 5. The primary contraindications for bupropion are:
- Seizure disorders or conditions that lower seizure threshold (including brain metastases, stroke)
- Concurrent MAO inhibitor use
- Closed-angle glaucoma 4
History of TD is not a contraindication to bupropion use.
Movement Disorder Considerations
While bupropion does not cause TD, rare case reports describe acute dystonic reactions with bupropion:
- These are acute dystonias, not tardive dyskinesia 6, 7
- Occur within 24-48 hours of dose initiation or escalation
- Resolve with dose reduction or discontinuation
- One isolated case report of TD associated with bupropion exists 8, but this is extraordinarily rare and causality is questionable given TD's typical association with dopamine-blocking agents
The distinction is critical: acute dystonia is an immediate, reversible reaction, while TD develops after prolonged exposure to dopamine blockers and may be permanent 1.
Dosing Recommendations
For patients with TD history requiring bupropion:
Standard dosing (no adjustment needed for TD history):
- Start: 150 mg once daily in the morning
- After 4 days: May increase to 300 mg once daily
- Maximum: 450 mg/day (though 300 mg is typical target) 5
Gradual titration minimizes seizure risk (the primary safety concern with bupropion), not movement disorder risk 5.
Monitoring
For patients with pre-existing TD on bupropion:
- Continue baseline TD monitoring using the Abnormal Involuntary Movement Scale (AIMS) every 3-6 months 1, 2
- This monitoring is for the underlying TD (caused by prior antipsychotic exposure), not due to bupropion
- Monitor for neuropsychiatric symptoms (depression, suicidal ideation) as per black box warning 4, 5
- No specific movement disorder monitoring is required beyond what's already indicated for TD
Clinical Algorithm
When prescribing bupropion to a patient with TD:
- Confirm TD is stable or improving (not actively worsening from ongoing antipsychotic use)
- Screen for actual contraindications: seizure history, brain lesions, MAO inhibitor use
- Start standard dosing: 150 mg daily × 4 days, then 300 mg daily
- Continue existing TD monitoring schedule (AIMS every 3-6 months)
- Do not add anticholinergics prophylactically (these can worsen TD) 1
Treatment of Underlying TD
If the patient requires active TD treatment while on bupropion, the recommended approach is:
First-line for moderate-to-severe TD: VMAT2 inhibitors (valbenazine or deutetrabenazine) 2, 9
- These can be safely combined with bupropion
- No drug-drug interaction concerns
Bupropion does not interfere with TD treatment and may be continued during TD management.
Common Pitfall
Do not confuse bupropion with antipsychotics. The evidence clearly shows TD is associated with dopamine receptor blocking agents 1, 2, 3, 10. Bupropion enhances dopaminergic transmission and belongs to a completely different pharmacologic class. Withholding bupropion from patients with TD history based on movement disorder concerns is not evidence-based and may deprive patients of effective antidepressant treatment.